Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
Silo Pharma (NASDAQ: SILO) has filed a new provisional patent application with the USPTO for its lead asset SPC-15, expanding its intellectual property portfolio. The patent covers a dual-action method and composition for treating stress-induced psychiatric disorders.
A preclinical study demonstrated that the combination of SPC-15, a serotonin type IV receptor (5-HT4R) agonist, with an N-methyl-D-aspartate receptor (NMDAR) antagonist showed significant improvements in behavioral outcomes and reduced severe stress-induced conditions. This technology was originally licensed through a collaboration with Columbia University.
The company has also recently filed a separate expanded provisional patent application focusing on chronic, combinatorial targeting of NMDARs and 5-HT4Rs to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia.
Silo Pharma (NASDAQ: SILO) ha presentato una nuova domanda di brevetto provvisorio presso l'USPTO per il suo principale asset SPC-15, ampliando il suo portafoglio di proprietà intellettuale. Il brevetto copre un metodo e una composizione a doppia azione per il trattamento dei disturbi psichiatrici indotti dallo stress.
Uno studio preclinico ha dimostrato che la combinazione di SPC-15, un agonista del recettore della serotonina di tipo IV (5-HT4R), con un antagonista del recettore N-metil-D-aspartato (NMDAR) ha mostrato significativi miglioramenti nei risultati comportamentali e ha ridotto le condizioni di stress grave. Questa tecnologia è stata originariamente concessa in licenza attraverso una collaborazione con la Columbia University.
L'azienda ha recentemente presentato anche una separata domanda di brevetto provvisorio ampliato che si concentra sul targeting combinatorio cronico dei NMDAR e dei 5-HT4R per estendere gli effetti comportamentali contro il comportamento perseverativo indotto dallo stress e l'iponeofagia.
Silo Pharma (NASDAQ: SILO) ha presentado una nueva solicitud de patente provisional ante la USPTO para su activo principal SPC-15, ampliando su cartera de propiedad intelectual. La patente cubre un método y una composición de doble acción para tratar trastornos psiquiátricos inducidos por el estrés.
Un estudio preclínico demostró que la combinación de SPC-15, un agonista del receptor de serotonina tipo IV (5-HT4R), con un antagonista del receptor N-metil-D-aspartato (NMDAR) mostró mejoras significativas en los resultados conductuales y redujo las condiciones graves inducidas por el estrés. Esta tecnología fue licenciada originalmente a través de una colaboración con la Universidad de Columbia.
La empresa también ha presentado recientemente una solicitud de patente provisional ampliada que se centra en el objetivo combinatorio crónico de los NMDAR y los 5-HT4R para extender los efectos conductuales contra el comportamiento perseverativo inducido por el estrés y la hiponeofagia.
시로 파마(Silo Pharma) (NASDAQ: SILO)는 USPTO에 주요 자산 SPC-15에 대한 새로운 임시 특허 출원을 하여 지적 재산 포트폴리오를 확장했습니다. 이 특허는 스트레스로 유발된 정신 장애를 치료하기 위한 이중 작용 방법 및 조성을 포함합니다.
전임상 연구에서는 세로토닌 IV형 수용체(5-HT4R) 작용제인 SPC-15와 N-메틸-D-아스파르트산 수용체(NMDAR) 길항제의 조합이 행동 결과에서 상당한 개선을 보였고 심각한 스트레스 유발 조건을 감소시켰습니다. 이 기술은 원래 콜럼비아 대학교와의 협력을 통해 라이센스되었습니다.
회사는 최근 NMDAR와 5-HT4R의 만성 복합 타겟팅에 중점을 둔 별도의 확장된 임시 특허 출원도 제출하여 스트레스 유발 지속적 행동 및 저신경탐색에 대한 행동 효과를 확장하고자 합니다.
Silo Pharma (NASDAQ: SILO) a déposé une nouvelle demande de brevet provisoire auprès de l'USPTO pour son actif principal SPC-15, élargissant ainsi son portefeuille de propriété intellectuelle. Le brevet couvre une méthode et une composition à double action pour traiter les troubles psychiatriques induits par le stress.
Une étude préclinique a démontré que la combinaison de SPC-15, un agoniste du récepteur de la sérotonine de type IV (5-HT4R), avec un antagoniste du récepteur N-méthyl-D-aspartate (NMDAR) a montré des améliorations significatives des résultats comportementaux et a réduit des conditions sévères induites par le stress. Cette technologie a été initialement licenciée grâce à une collaboration avec l'Université de Columbia.
L'entreprise a également récemment déposé une demande de brevet provisoire élargie distincte se concentrant sur le ciblage combinatoire chronique des NMDAR et des 5-HT4R pour prolonger les effets comportementaux contre le comportement persévératif induit par le stress et l'hyponeophagie.
Silo Pharma (NASDAQ: SILO) hat einen neuen vorläufigen Patentantrag beim USPTO für sein Hauptprodukt SPC-15 eingereicht und damit sein geistiges Eigentum erweitert. Das Patent umfasst eine duale Methode und Zusammensetzung zur Behandlung von stressinduzierten psychiatrischen Störungen.
Eine präklinische Studie zeigte, dass die Kombination von SPC-15, einem Agonisten des Serotoninrezeptors Typ IV (5-HT4R), mit einem Antagonisten des N-Methyl-D-Aspartat-Rezeptors (NMDAR) signifikante Verbesserungen der Verhaltensresultate und eine Verringerung schwerer stressbedingter Zustände aufwies. Diese Technologie wurde ursprünglich durch eine Zusammenarbeit mit der Columbia University lizenziert.
Das Unternehmen hat kürzlich auch einen separaten erweiterten vorläufigen Patentantrag eingereicht, der sich auf die chronische, kombinierte Zielverfolgung von NMDARs und 5-HT4Rs konzentriert, um die Verhaltenswirkungen gegen stressbedingtes perseveratives Verhalten und Hyponeophagie zu verlängern.
- Filing of new provisional patent application strengthening IP protection for lead asset SPC-15
- Preclinical study showed significant improvement in behavioral outcomes
- Multiple patent applications pending to expand protection of core technology
- Product still in early development stage (preclinical)
- No guarantee of patent approval or commercial success
Insights
This patent filing represents a significant strategic development for Silo Pharma's intellectual property portfolio, particularly in the rapidly evolving field of psychiatric pharmaceuticals. The dual-mechanism approach combining a 5-HT4R agonist with an NMDAR antagonist is particularly noteworthy, as it addresses multiple neural pathways involved in stress-induced disorders. This approach could potentially offer superior efficacy compared to single-target treatments.
The provisional patent strategy deserves careful attention. While it provides immediate protection and establishes a priority date, Silo will have 12 months to file a complete patent application. This timing suggests a well-planned IP strategy, building upon their existing patents from the Columbia University collaboration. The expanded patent coverage for chronic, combinatorial targeting indicates a comprehensive approach to protect various aspects of the technology.
From a market perspective, the preclinical success in reducing stress-induced conditions positions Silo in the growing mental health therapeutics sector, valued at over
The strategic value extends beyond the immediate patent filing. This IP expansion strengthens Silo's negotiating position for potential partnerships or licensing agreements, while also creating barriers to entry for competitors. The combination treatment's demonstrated efficacy in preclinical studies suggests potential applications across multiple stress-related conditions, possibly expanding the addressable market.
SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders
SARASOTA, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15.
Silo currently has patents issued and numerous expanded patent applications pending for SPC-15, a technology that was originally licensed through a collaboration with Columbia University.
The provisional patent covers a dual-action method and composition for combating stress-induced pathophysiology and reducing a variety of stress-induced psychiatric behaviors. A preclinical study of SPC-15, a serotonin type IV receptor (5-HT4R) agonist, combined with an N-methyl-D-aspartate receptor (NMDAR) antagonist demonstrated significant improvement in behavioral outcomes and a marked reduction in severe stress-induced conditions.
“We believe that the SPC-15 combination treatment is showing promise in multiple stress-induced behaviors and disorders. This provisional patent application, if approved and the patent issued, will augment and expand the existing patents on this technology which we originally acquired through our global license agreement,” said Eric Weisblum, CEO of Silo.
Silo recently filed a separate expanded provisional patent application covering the chronic, combinatorial targeting of NMDARs and 5-HT4Rs to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia.
About SPC-15
SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA’s streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What is the new patent application filed by Silo Pharma (SILO) for SPC-15 in February 2025?
What were the results of SILO's preclinical study for SPC-15 combination treatment?
How many patent applications does Silo Pharma (SILO) currently have for SPC-15?
Where did Silo Pharma originally obtain the SPC-15 technology?
